Beam Therapeutics (BEAM) Operating Leases (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Operating Leases data on file, last reported at $135.8 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $135.8 million, down 6.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.8 million (down 6.26% YoY), and the FY2025 annual result was $139.8 million, down 5.54% from the prior year.
• Operating Leases eased to $135.8 million in Q1 2026 per BEAM's latest filing, from $139.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $168.6 million in Q4 2022 and troughed at $135.8 million in Q1 2026.
• A 5-year average of $152.4 million and a median of $152.6 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2024: Operating Leases climbed 25.08% in 2022, then declined 7.48% in 2024.
• A 5-year view of Operating Leases shows it stood at $168.6 million in 2022, then declined by 5.17% to $159.9 million in 2023, then fell by 7.48% to $148.0 million in 2024, then decreased by 5.54% to $139.8 million in 2025, then declined by 2.8% to $135.8 million in 2026.
• Business Quant data shows BEAM's Operating Leases at $135.8 million in Q1 2026, $139.8 million in Q4 2025, and $138.7 million in Q3 2025.